Germany’s Merck will get $850 million upfront to work on the product, but Pfizer downgrades its 2014 EPS view as a result of the transaction.
Source : MarketWatchCom
Germany’s Merck will get $850 million upfront to work on the product, but Pfizer downgrades its 2014 EPS view as a result of the transaction.
Source : MarketWatchCom